In just 2 weeks time, the highly anticipated conference on Advances and Progress in Drug Design, will return to London and open its doors to leading pioneers from across the globe to discuss, debate and share ideas and challenges facing the drug design arena. Key areas to be addressed will include structure based drug design, water applications, fragment based drug design, lead optimisation challenges and molecular design.
Due to high demand, SMi Group Ltd have announced that availability to attend the 13th annual instalment is now strictly limited. Registration will be closing soon. Those who are interested can still register online at www.drug-design.co.uk
Conference chairman John Mathias, Senior Director and Head of Medicinal Chemistry at Pfizer, commented:
"Advances & Progress in Drug Design offers an unparalleled snapshot of current trends and future horizons in drug design. Bringing together leaders in the fields of computational, structural & biophysical methods to showcase applications across a wide range of target classes, at every stage of the drug discovery process, the meeting offers a unique opportunity to share and debate the best strategies to improve drug discovery going forward and discuss diverse questions such as the status of fragment-based lead optimization, current hit identification methods and the potential of epigenetic-target based discovery."
Key note addresses will include presentations from D. E. Shaw Research, Pfizer, Roche, MedImmune, Astex Pharmaceuticals, Bayer, Sanofi-Aventis and Novartis. Click here to view full speaker line up and conference agenda.
Advances and Progress in Drug Design: Delivering Practical Solutions to Drug Delivery Challenges 17-18 February 2014 , Marriott Regents Park Hotel, London, UK, www.drug-design.co.uk